The "next steps" section of the announcement says explicitly that breast cancer FTO is one of the next steps.
I agree that it makes sense to complete that before starting either of the two FTO studies already announced.
Because the FTO pillar is binary; bisantrene is either effective in all FTO-overexpressed cancers or in none of them.
The "next steps" section of the announcement says explicitly...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.59 |
Change
0.055(3.59%) |
Mkt cap ! $260.7M | |||
| Open | High | Low | Value | Volume |
| $1.56 | $1.60 | $1.53 | $79.91K | 51.96K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 25 | $1.55 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.60 | 23239 | 1 |
View Market Depth
| Last trade - 16.10pm 17/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |